Share your videos with the world

Dendreon Corporation (Nasdaq: DNDN) announced significant milestones that support broad availability for on-label use of PROVENGE® (sipuleucel-T), the first autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer (mCRPC). To view Multimedia News Release, go to http://www.multivu.com/mnr/50924-dendreon-provenge-cellular-immunotherapy